Evidence map›Paper›PMID 37548690›Full record

ReviewAnnals of hematology2024

N6-methyladenosine RNA modifications: a potential therapeutic target for AML.

Rong Hu, Peiyun Liao, Binyan Xu, Yingqi Qiu, Honghao Zhang, Yuhua Li

Abstract readReview
PubMed Publisher
In one paragraph

Review in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Single-cell transcriptome profiling of mMolecular biomedicine · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rong HuDepartment of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China.
Peiyun LiaoDepartment of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China.
Binyan XuDepartment of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China.
Yingqi QiuDepartment of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China.
Honghao ZhangDepartment of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China.
Yuhua LiDepartment of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China. liyuhua1974@outlook.com.ORCID http://orcid.org/0000-0002-0982-6680

Funding

Guangdong Basic and Applied Basic Research Foundation 2021A1515110974the Frontier Research Program of Guangzhou Regenerative Medicine and Health Guangdong Laboratory 2018GZR110105014the National Natural Science Foundation of China U2001224
6 · The paper itself

Abstract

N6-methyladenosine (m6A) RNA modification has recently emerged as an essential regulator of normal and malignant hematopoiesis. As a reversible epigenetic modification found in messenger RNAs and non-coding RNAs, m6A affects the fate of the modified RNA molecules. It is essential in most vital bioprocesses, contributing to cancer development. Here, we review the up-to-date knowledge of the pathological functions and underlying molecular mechanism of m6A modifications in normal hematopoiesis, leukemia pathogenesis, and drug response/resistance. At last, we discuss the critical role of m6A in immune response, the therapeutic potential of targeting m6A regulators, and the possible combination therapy for AML.

Indexed as

AdenosineLeukemia, Myeloid, AcuteAnimalsDrug Resistance, NeoplasmEpigenesis, GeneticHematopoiesisHumansMolecular Targeted TherapyRNA, NeoplasmRNA Processing, Post-TranscriptionalAdenosineN-methyladenosineRNA, NeoplasmAcute myeloid leukemiaImmunomodulationN6-methyladenosine RNA modificationTargeted therapy

Identifiers

PMID37548690

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.